Bridgebio Pharma, Inc. number of employees

Bridgebio Pharma, Inc. reported 834 employees at December 31, 2025 in its latest annual report, up 109 (15.0%) on the year before. That compares with 576 at December 31, 2021. Revenue per employee was $602,010.

Headcount by year

Fiscal year end	Employees	Change	Revenue per employee	Source
December 31, 2025	834	+109 (15.0%)	$602,010	10-K, filed February 24, 2026
December 31, 2024	725	+175 (31.8%)	$306,072	10-K, filed February 20, 2025
December 31, 2023	550	+158 (40.3%)	$16,915	10-K, filed February 22, 2024
December 31, 2022	392	−184 (31.9%)	$198,082	10-K, filed February 23, 2023
December 31, 2021	576	—	$121,035	10-K, filed February 25, 2022

What the annual reports say

As of December 31, 2025, we had 834 full-time employees and 5 part-time employees. 2025 annual report
As of December 31, 2024, we had 725 full-time employees and 5 part-time employees. 2024 annual report
We have provided below additional details on some of our core human resources processes. 43 As of December 31, 2023, we had 550 full-time employees and six part-time employees. 2023 annual report
As of December 31, 2022, we had 392 full-time employees and four part-time employees. 2022 annual report
As of December 31, 2021, we and our subsidiaries, to which we refer as our affiliates, had 576 full-time employees and two part-time employees. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: BBIO vs KNSA BBIO vs BCRX BBIO vs IONS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bridgebio Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bridgebio Pharma, Inc.